Glaukos Corporation (GKOS)
Glaukos Corporation (GKOS) is a healthcare company (medical devices) based in the United States. The share price is $245.45, up 0.23% on the day, which values the company at $14.53B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $245.45+0.23% today
- Market value
- $14.53B
- Forward P/E
- 175.3×
- Funk Score
- 37/100
- Against its own history
- Well above its usual priceusual price $85.10
- 200-week average
- $107.02129% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Glaukos Corporation in more detail
GKOS trades at 175.3× next year's expected earnings, 21.0× sales. Measured against its own history, the price is 188% above what its usual multiples would imply ($85.10) — well above its usual price. It sits 129% above its 200-week average of $107.02.
Over the last five fiscal years Glaukos Corporation has compounded revenue 17.7% a year. Its Funk Score is 37 out of 100 (financial strength 5.6, profitability 0.4, growth 9.0, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
4 of the superinvestors tracked here hold GKOS, including Brandon Haley (0.5% of the portfolio), Primecap team (0.3% of the portfolio), Israel Englander (0.1% of the portfolio).
Superinvestors holding GKOS
4 of the investors tracked here report a position in their latest 13F filing.
- Brandon Haley Holocene Advisors0.49% of portfolio · $211.7M · added · Q2 2026
- Primecap team Primecap Management0.31% of portfolio · $505.1M · added · Q3 2026
- Israel Englander Millennium Management0.15% of portfolio · $221M · added · Q2 2026
- Polen Capital team Polen Capital Management0.06% of portfolio · $5.2M · added · Q3 2026
Health Care companies of similar size
- Jazz PharmaceuticalsJAZZ
- SolventumSOLV
- BridgeBio PharmaBBIO
- Summit TherapeuticsSMMT
- Encompass HealthEHC
- BrightSpring Health ServicesBTSG
- Baxter InternationalBAX
- Elanco Animal HealthELAN
- Smith & NephewSNN
- PenumbraPEN
- Dr. Reddy's LaboratoriesRDY
- Align TechnologyALGN
Side by side:GKOS vs SMMT (Glaukos Corporation vs Summit Therapeutics)GKOS vs EHC (Glaukos Corporation vs Encompass Health)GKOS vs BTSG (Glaukos Corporation vs BrightSpring Health Services)GKOS vs BAX (Glaukos Corporation vs Baxter International)GKOS vs ELAN (Glaukos Corporation vs Elanco Animal Health)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Glaukos Corporation (GKOS): questions and answers
What is Glaukos Corporation's market cap?
Glaukos Corporation is valued at $14.53B at a share price of $245.45.
Is GKOS overvalued or undervalued?
Against its own history, GKOS is well above its usual price: the price is 188% above the $85.10 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is GKOS above its 200-week moving average?
Yes. GKOS is 129.4% above its 200-week average of $107.02. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Glaukos Corporation growing?
Over the last five fiscal years Glaukos Corporation's revenue grew 17.7% a year; over ten years revenue grew 21.6% a year.
Does GKOS pay a dividend?
Glaukos Corporation does not currently pay a regular dividend.
Which famous investors own GKOS?
In their latest quarterly filings, Brandon Haley (0.5% of the portfolio), Primecap team (0.3% of the portfolio), Israel Englander (0.1% of the portfolio), Polen Capital team (0.1% of the portfolio) hold GKOS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Glaukos Corporation (GKOS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/GKOS
Underlying data: Yahoo Finance; company filings with the SEC.